Mitsubishi Chemical Medience Markets POCT Device To The U.S. And Canada
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based medical device maker Mitsubishi Chemical Medience began marketing compact automated immunoassay analyzer Pathfast to the U.S. and Canada. FDA approved the device along with N-Terminal proBNP (brain natriuretic peptide) testing as a marker of congestive heart failure. A point-of-care testing device, PATHFAST is used for night and emergency care testing and has been marketed in Europe and Korea. The company has signed distribution agreements with North American distributors and hopes to get six more test reagents approved by the FDA by this December. Mitsubishi Chemical estimates within three years that Pathfast will reach 10 percent of the BNP testing market with ¥4 billion in sales. (Click here for more - Japanese language
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.